UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934 

 

Date of report (Date of earliest event reported): July 6, 2018

 

ACRO BIOMEDICAL CO., LTD.

(Exact name of registrant as specified in Charter)

 

Nevada

 

333-207765

 

47-1950356

(State or other jurisdiction of

incorporation or organization)

 

(Commission File No.)

 

(IRS Employee Identification No.)

 

2175 Visionary Way, Suite 1160; Fishers, Indiana 46038

  (Address of Principal Executive Offices)

 

(317) 286-6788

  (Registrant’s Telephone number)

Copies to:

Asher S. Levitsky PC

Ellenoff Grossman & Schole LLP

1345 Avenue of the Americas, Suite 1100

New York, New York 10105

Phone: (646) 895-7152

Fax: (212) 370-7889

E-mail: alevitsky@egsllp.com

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨ Soliciting material pursuant to Rule 14a-12(b) under the Exchange Act (17 CFR 240.14a-12(b))

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 
 
 
 

 

Item 4.01. Changes in Registrant’s Certifying Accountant

 

On July 6, 2018, the Company’s sole director approved the engagement of Paritz & Company, P.A. ("Paritz") as the independent registered public accounting firm for the Company.

 

During the two fiscal years prior to Paritz's engagement by the Company and any subsequent interim period prior to its engagement, the Company did not consult with Paritz with respect to any of (i) the application of accounting principles to a specified transaction, either completed or proposed; (ii) the type of audit opinion that might be rendered on the Company’s financial statements; or (iii) any matter that was either the subject of a disagreement (as defined in Item 304(a)(1)(iv) of Regulation S-K) or an event of the type described in Item 304(a)(1)(v) of Regulation S-K.

 

 
2
 
 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Date: July 6, 2018

 

ACRO BIOMEDICAL CO., LTD.

 

 

 

 

 

 

By:

/s/ Pao-Chi Chu

 

 

 

Pao-Chi Chu

 

 

 

Chief Executive Officer

 

 

 

3

 

 

Arco Biomedical (CE) (USOTC:ACBM)
Gráfico Histórico do Ativo
De Fev 2025 até Mar 2025 Click aqui para mais gráficos Arco Biomedical (CE).
Arco Biomedical (CE) (USOTC:ACBM)
Gráfico Histórico do Ativo
De Mar 2024 até Mar 2025 Click aqui para mais gráficos Arco Biomedical (CE).